 Home > Active Ingredient News > Study of Nervous System > NEJM: Should patients with depression in primary care maintain or stop antidepressants?

NEJM: Should patients with depression in primary care maintain or stop antidepressants?

 Last Update: 2021-10-09
 Source: Internet
 Author: User

Tags

insomnia anxiety depression

hemp care

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Patients with depression who are treated in primary care practice may take antidepressants for a long time

Recently, a research article was published in the top medical journal NEJM.

The main outcome of the study was the first recurrence of depression during the 52-week trial period, as assessed in the time-to-event analysis

A total of 1466 patients in the study were screened

Screening

It can be seen that among the patients who felt good in primary care practice and stopped antidepressant treatment, those who were assigned to the discontinuation group had a higher risk of recurrence of depression at 52 weeks than those who were assigned maintenance treatment

Among patients who felt good in primary care practice and discontinued antidepressant treatment, those who were assigned to the discontinuation group had a higher risk of recurrence of depression at 52 weeks than those who were assigned maintenance therapy

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Scopolamine hot sale CAS 51-34-3 wholesale Scopolamine powder

CAS No.: 51-34-3

Pharmacy Grade

$3.2-3.5/KG FOB

Paroxetine CAS 61869-08-7

CAS No.: 61869-08-7

Pharmacy Grade

$88-98/KG FOB

Scopolamine Hydrobromide CAS 114-49-8

CAS No.: 114-49-8

Pharmacy Grade

$118-128/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.